Myelofibrosis - 46 Studies Found
| Not yet recruiting |
: A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis : Myelofibrosis : 2017-05-05 :
|
| Terminated |
: Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis : Myelofibrosis : 2008-04-24 : Drug: bevacizumab (Avastin) 15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 w |
| Active, not recruiting |
: Allogeneic Stem Cell Transplantation for Myelofibrosis : Myelofibrosis : 2007-05-15 :
|
| Active, not recruiting |
: Study of Ruxolitinib for Patients With Myelofibrosis (MF) : Myelofibrosis : 2016-05-20 :
|
| Completed |
: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis : Myelofibrosis : 2016-03-21 :
|
| Completed |
: Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients : Myelofibrosis : 2011-04-21 : Drug: Ruxolitinib Ruxolitinib was supplied as SR and IR formulated tablets. |
| Completed |
: Quantitative MRI for Myelofibrosis : Myelofibrosis : 2013-10-25 : Procedure: T1 Weighted MRI (magnetic resonance imaging) En |
| Completed |
: Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis : Myelofibrosis : 2007-12-11 : Drug: Fludarabine, Melphalan +/- ATG Conditioning regimen |
| Suspended |
: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor : Primary Myelofibrosis : 2015-04-21 :
|
| Completed |
: Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis : Myelofibrosis : 2015-02-06 :
|